Cost-effectiveness watchdogs skewer Novartis' MS drug Mayzent and J&J's depression spray Spravato

Novartis' MS drug Mayzent and J&J's depression spray Spravato were approved by the FDA in March and priced at $88,500 and $32,400 per year, respectively. But neither drug is cost effective, said ICER, which issued an affordability alert on Spravato.